NCT05166837

The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects

A Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Phase Ⅰa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of STSA-1002Following Intravenous Infusion in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

A randomized, double-blind, placebo-controlled, single-ascending dose Phase Ⅰa study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of STSA-1002 following intravenous infusion in healthy subjects

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	STSA-1002 injection	Intravenous injection
DRUG	Placebo	Intravenous injection
DRUG	STSA-1002 injection	Intravenous injection
DRUG	Placebo	Intravenous injection
DRUG	STSA-1002 injection	Intravenous injection
DRUG	Placebo	Intravenous injection
DRUG	STSA-1002 injection	Intravenous injection
DRUG	Placebo	Intravenous injection
DRUG	STSA-1002 injection	Intravenous injection
DRUG	Placebo	Intravenous injection

Timeline

• Start date: 2022-01-10
• Primary completion: 2023-01-12
• Completion: 2023-01-12
• First posted: 2021-12-22
• Last updated: 2023-12-20

Locations

5 sites across 1 country: China